Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/8005
Title: The meta-analytic framework for the evaluation of surrogate endpoints in clinical trials
Authors: MOLENBERGHS, Geert 
BURZYKOWSKI, Tomasz 
ALONSO ABAD, Ariel 
ASSAM NKOUIBERT, Pryseley 
TILAHUN ESHETE, Abel 
BUYSE, Marc 
Issue Date: 2008
Publisher: ELSEVIER SCIENCE BV
Source: JOURNAL OF STATISTICAL PLANNING AND INFERENCE, 138(2). p. 432-449
Abstract: For a number of reasons. Surrogate endpoints are considered instead of the so-called true endpoint in clinical studies. especially when such endpoints can be measured earlier, and/or with less burden for patient and experimenter. Surrogate endpoints may occur more frequently than their standard counterparts. For these reasons, it is not surprising that the use of surrogate endpoints in clinical practice is increasing. Building on the seminal work of Prentice [ 1989. Surrogate endpoints in clinical trials: definitions and operational criteria. Statist. Med. 8, 43 1-440] and Freedman et a]. [ 1992. Statistical validation of intermediate endpoints for chronic diseases. Statist. Med. 11, 167-178], Buyse et al. [2000. The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics 1, 49-67] framed the evaluation exercise within a meta-analytic setting, in an effort to overcome difficulties that necessarily surround evaluation efforts based on a single trial. In this paper, we review the meta-analytic approach for continuous outcomes, discuss extensions to non-normal and longitudinal settings, as well as proposals to unify the somewhat disparate collection of validation measures currently on the market. Implications for design and for predicting the effect of treatment in a new trial, based on the surrogate, are discussed. Two case studies are analyzed, one in schizophrenia and one in opthalmology. (C) 2007 Elsevier B.V. All rights reserved.
Notes: Hasselt Univ, Ctr Stat, Diepenbeek, Belgium. Int Inst Drug Dev, Louvain, Belgium.Molenbergh, G, Hasselt Univ, Ctr Stat, Diepenbeek, Belgium.geert.molenberghs@uhasselt.be
Keywords: hierarchical model; likelihood reduction factor; meta-analysis; random-effects model; surrogate endpoint; surrogate threshold effect;hierarchical model; likelihood reduction factor; meta-analysis; random-effects model; surrogate endpoint; surrogate threshold effect
Document URI: http://hdl.handle.net/1942/8005
ISSN: 0378-3758
e-ISSN: 1873-1171
DOI: 10.1016/j.jspi.2007.06.005
ISI #: 000253067200010
Rights: © 2007 Elsevier B.V. All rights reserved.
Category: A1
Type: Journal Contribution
Validations: ecoom 2009
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
The Meta-analytic Framework for the Evaluation.pdfPeer-reviewed author version225.37 kBAdobe PDFView/Open
a.pdf
  Restricted Access
Published version239.85 kBAdobe PDFView/Open    Request a copy
Show full item record

SCOPUSTM   
Citations

11
checked on Sep 3, 2020

WEB OF SCIENCETM
Citations

12
checked on Mar 21, 2024

Page view(s)

84
checked on Sep 7, 2022

Download(s)

200
checked on Sep 7, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.